Drugs & Medical Devices
Get ready for the next wave of pharmaceutical litigation with HarrisMartin's Drugs & Medical Devices. This reporter will keep you one step ahead of drug and medical device litigation with in-depth investigations, guest commentaries and objective courtroom coverage on today's and tomorrow's hottest drugs and supplements.
SEARCH THE ARCHIVES
Issue #7, July 2002
A California appeals court has held that an insurer does not have a duty to defend the manufacturer of Metabolife 356 in a class action filed against the company because the underlying third-party complaint does not allege
A New York court has ruled that the testimony of doctors who treated a woman who died after taking an ephedra-containing product is material and necessary to resolve a lawsuit filed
Judge Rules on Defendant's <i>Daubert</i> Motion, Allows <br>Expert Witnesses to Testify in Alabama Ephedra Case
A federal judge has denied a defense motion to preclude the testimony of two expert witnesses in a lawsuit against the manufacturers of an ephedra-containing Metabolife product
Judge Grants Motion to Stay Baycol Class Action, Cites Inability to Estimate Value of Medical Monitoring Claims
The inability to estimate the value of medical monitoring claims as a whole was the basis for a federal judge's recent decision to grant a motion to stay proceedings in a Baycol products liability class action
A Louisiana woman's products liability lawsuit against the manufacturers of products containing PPA has been dismissed by a federal judge who decided the plaintiff failed to include causes of action
A federal judge in Louisiana has dismissed two cases against the manufacturers of products containing PPA, stating the plaintiffs' allegations are ''well outside'' the scope
The U.S. Department of Health and Human Services has announced plans for a new study concerning the safety of ephedra and an increased effort to restrict the illegal sale of products containing synthetic ephedrine
The new FDA-approved warning labels accompanying the arthritis drug Celebrex will continue to educate patients and physicians of the potential risk of gastrointestinal events associated with the anti-inflammatory drug, and include new information for elde
A federal judge issued a scathing memorandum directed at attorneys for GlaxoSmithKline, noting discrepancies of its responsive pleading to a products liability action involving the drug Baycol.
A federal judge has granted a motion to remand a Lotronex product liability suit after finding that the defendants failed to conclusively prove the existence of federal jurisdiction and fraudulent joinder among non-diverse defendants in a lawsuit against